BCMA

Leah SherwoodPrint | March 10, 2023
In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies.
Read More
Kerri FitzgeraldMyeloma | November 16, 2022
Belantamab mafodotin is a BCMA targeted antibody drug conjugate approved for adult patients...
Noopur Raje, MDMyeloma | January 31, 2023
Noopur Raje, MD, says the future of BCMA-directed CAR T-cell therapies may lie with next-generation agents such as bb21217.
Advertisement
Noopur Raje, MDMyeloma | November 14, 2022
Noopur Raje, MD, discusses the safety and efficacy results of the CRB-402 trial.
Advertisement
Advertisement
Advertisement
Editorial Board